Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2019-05-31 Audit Report / Informat…
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Audit Report / Information Classification · 90% confidence The document contains detailed disclosures about related party transactions, including names and relationships of key management personnel and their relatives, as well as financial transactions such as salaries, rent, and software purchases during the fiscal year 2018-19. This type of information is typically found in the notes to financial statements or audit reports, focusing on governance and compliance with accounting standards. The document is relatively short (2454 characters) and does not present a full financial report or comprehensive management discussion. It is not an announcement or a brief summary but a detailed disclosure related to audit and accounting principles. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2019
2019-05-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is extremely short (407 characters) and consists only of addresses to stock exchanges (BSE and NSE) with no substantive content or financial data. There is no indication of a report, announcement, or detailed information. It appears to be a brief communication or cover letter without any report attached or described. Given the lack of content and the nature of the text, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other categories.
2019-05-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a full transcript of Laurus Labs Limited's Q4 FY2019 earnings conference call held on May 3rd, 2019. It includes detailed management commentary on financial results, business highlights, segment performance, strategic partnerships, product filings, market outlook, and a Q&A session with analysts. The presence of detailed financial figures, business updates, and management discussion confirms this is a call transcript. There is no indication that this is a brief earnings release or a regulatory announcement. The length and content clearly match the definition of a Call Transcript (CT).
2019-05-08 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed communication from Laurus Labs Limited dated May 2, 2019, addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It includes the audited standalone and consolidated financial results for the quarter and year ended March 31, 2019, along with audit reports from Deloitte Haskins & Sells LLP. The document also mentions a dividend recommendation for FY 2019 and provides detailed financial statements including income, expenses, profit, comprehensive income, balance sheet, and equity and liabilities. The presence of full financial data, audit reports, and comprehensive financial statements for the fiscal year indicates this is a full annual report document rather than a brief announcement or a regulatory filing. The length (15,000 characters) and detailed financial content confirm it is not a short announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2019
2019-05-03 English
Book Closure
Notice of Dividend Amount Classification · 90% confidence The document is very short (397 characters) and contains information about book closure dates and record dates related to an Annual General Meeting and payment of dividend. It does not contain any financial statements or detailed report content. This type of announcement typically relates to dividend payment and AGM scheduling. Given the mention of dividend payment and AGM, the document fits best under Notice of Dividend Amount (DIV) as it announces dividend-related dates and AGM details rather than the full AGM materials or annual report.
2019-05-02 English
Investor Presentation
Regulatory Filings
2019-05-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.